Clinical Trials

Overview

About this study

Concerns about the use of DEX as a standard anti-emetic for women with ovarian cancer promoted us to examine its impact on drug sensitivity. Assessment in both cell lines (in vitro) and patient-derived xenograft models (in vivo) shows that, DEX administration decreases platinum induced tumor killing. This effect is observed in models that express GcR and is likely through the activation of genes modulating platinum sensitivity. Importantly, mechanistic studies conducted in our lab confirm the induction of several proteins involved in metal-binding and regulation of cell death. As a result, there is substantial interest in being able to detect and quantify DEX- induced genes in clinical material.

To test this idea, we propose to analyze the expression of the above target genes (MT2A, MT1X, MT1E, SGK1 and BIRC3) and NR3C1 (encoding GcR) in circulating tumor cells from patients receiving dexamethasone prior to chemotherapy. 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Participating Mayo Clinic locations

More information